OCS
Oculis Holding AG
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
No implied move.
Oculis Holding AG
Expected move
No implied move.
Oculis Holding AG
7.17
−0.46 · −6.05%
No other changes.
No other changes.
| Manager | Value | % base | |
|---|---|---|---|
| EQT Fund Management S.a r.l. | $96.4M | 29.83% | +17.80% |
| Standard Life Aberdeen | $30.0M | 9.27% | +23.63% |
| Millennium | $28.3M | 8.77% | +123.70% |
| Pivotal bioVenture Partners Investment Advisor | $20.9M | 6.47% | −10.36% |
| Citadel | $14.3M | 4.43% | +539.62% |
| Manager | Value | % base | |
|---|---|---|---|
| EQT Fund Management S.a r.l. | $96.4M | 29.83% | +17.80% |
| Standard Life Aberdeen | $30.0M | 9.27% | +23.63% |
| Millennium | $28.3M | 8.77% | +123.70% |
| Pivotal bioVenture Partners Investment Advisor | $20.9M | 6.47% | −10.36% |
| Citadel | $14.3M | 4.43% | +539.62% |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Oculis Holding AG.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Oculis Holding AG.
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Annual filing, covered
20-F parsed · Mar 4 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Mar 4 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.